You are here: Industry Insights > inflammatory diseases

News List

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member firstwordpharma
August 24, 2021
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company") today announced Mr. Jiang Bian has joined the Company as General Counsel & Chief Compliance Officer, effective August 20, 2021.
Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases pharmafocusasia
March 20, 2019
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases.
Patients switch to lower dose of Pfizer’s RA pill after safety signal pharmaphorum
February 22, 2019
Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patients at high risk of cardiovascular events.
J&J ends 2018 on a high, but coming year looks shaky pharmaphorum
January 24, 2019
Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition to some of its top products starts to have an impact on revenues.
Sanofi pays Denali $125M to buy into RIPK1 program 2. Biotech Sanofi pays Denali $125M to buy into RIPK1 program fiercebiotech
November 02, 2018
Sanofi is paying $125 million (€110 million) upfront for a stake in two RIPK1 inhibitors in development at Denali. The agreement covers small molecules designed to treat multiple...
European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) for the Treatment of Certain Inflamma americanpharmaceuticalreview
March 27, 2017
Amgen has announced that the European Commission (EC) has granted marketing authorization for AMGEVITA™ (biosimilar adalimumab1) in all available indications.
Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory pharmaasia
January 24, 2017
Single subconjunctival injection of Brimapitide, after ocular surgery shown to be non-inferior to dexamethasone eye drops given 4 times daily for 21 days.